Tradjenta and Metformin Sing a Duet

March 16th, 2012

written by Michael O’Leary
If you are taking metformin and Tradjenta to control your type 2 diabetes, Eli Lilly and Company has a new combination drug for you.

With a name that sounds more like a drug you’d buy at a cantina in Tijuana, Jentadueto was launched for U.S. sales with a Lilly press release Mar. 7. Developed in conjunction with its German partner Boehringer Ingelheim, Jentadueto combines the DPP-4 inhibitor in Lilly’s Tradjenta with metformin in a twice-daily pill. (Published site)

Do Some Diabetes Drugs Actually Help Your Heart?

September 30th, 2011

written by Michael O’Leary
While looking to find harmful effects of type 2 diabetes drugs on the heart and cardiovascular system, researchers were surprised to find that at least one class of these drugs appear to actually help prevent such effects.

As reported on by MedPage Today at the European Association for the Study of Diabetes meeting last week in Lisbon, Portugal, the researchers found that the class of drugs, called gliptins, were associated with 30 percent reduction in the risk of a major heart-related event, such as a heart attack, compared to diabetes patients who were taking another drug or placebo.

In the wake of the development of heart-related side effects of a cancer drug, called Avandia, last year, the FDA required drug companies to assess the cardiovascular risks of some of the new diabetes drugs.  (Link to published site)

What’s the Best Drug for Type 2 Diabetes? The Answer Isn’t Simple

September 1st, 2011 by Ryan Luce No Comments

Written by Michael O'Leary

With all the new FDA-approved drugs for type 2 diabetes lately, the question arises, is your current prescription the best for you? With names like Onglyza, Januvia, Byetta, Prandin, Tradjenta, metformin, Amaryl, it can be confusing even to know what to ask your doctor.

In a “best evidence review” published Aug. 30 in MedScape News, Dr. Charles Vega, associate professor in the Department of Family Medicine at the University of California, Irvine, compares the effectiveness and safety of all the medications for type 2 including the newest ones being marketed. At least that’s what he wanted to do. (Link to published site)